Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

98.36 -2.38 (-2.37%)
Streaming Delayed Price Updated: 11:48 AM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 170,278
Open 100.25
Bid (Size) 98.03 (200)
Ask (Size) 98.69 (200)
Prev. Close 100.74
Today's Range 96.69 - 100.26
52wk Range 44.04 - 107.84
Shares Outstanding 62,577,897
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases. 
Via The Motley Fool

Performance

YTD
+12.8%
+12.8%
1 Month
-6.7%
-6.7%
3 Month
+19.3%
+19.3%
6 Month
+16.0%
+16.0%
1 Year
+115.8%
+115.8%

More News

Read More
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
Via ACCESS Newswire
News headline image
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Via ACCESS Newswire
News headline image
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
Via MarketMinute
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
Via ACCESS Newswire
News headline image
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Via ACCESS Newswire
News headline image
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Protagonist (PTGX) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
Via ACCESS Newswire
News headline image
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?
Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?
Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?
The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market
What is the current price of Protagonist Therapeutics, Inc. - Common Stock?
The current price of Protagonist Therapeutics, Inc. - Common Stock is 98.36
When was Protagonist Therapeutics, Inc. - Common Stock last traded?
The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 05/19/26 11:48 AM ET
What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?
The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 6.15B
How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?
Protagonist Therapeutics, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.